CD274 and non-small cell lung carcinoma: Goldberg et al. [10] illustrated that pembrolizumab has a good curative effect on NSCLC patients with brain metastases with PD-L1 ≥ 1%, and no serious AEs occur during treatment, indicating its safety and effectiveness.